- Valeo Pharma Inc. (VPH) has signed a commercial services agreement with Veru Inc. for use of sabizabulin to treat COVID-19 in Canada
- Sabizabulin is a novel antiviral and anti-inflammatory compound used to treat hospitalized COVID-19 patients
- The compound showed a 55.20 per cent reduction in related mortality rates
- It also showed a reduction in days spent in the ICU
- Valeo Pharma Inc. (VPH) is unchanged, trading at $0.58 per share as of 11:36 a.m. ET
Valeo Pharma (VPH) has signed a commercial services agreement with Veru for use of sabizabulin to treat COVID-19 in Canada.
Sabizabulin is a novel antiviral and anti-inflammatory compound used to treat hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome and death.
Steve Saviuk, CEO of Valeo, commented,
“Provincial healthcare systems across the country are still battling with high numbers of COVID-19 hospitalized patients and related deaths. In a pivotal.”
The company stated a phase three study for sabizabulin showed a 55.20 per cent reduction in related mortality rates compared to placebo treatment.
“It also showed a significant reduction of days in ICU. Veru plans to pursue an expedited review process with the Canadian healthcare authorities with the objective of making sabizabulin available in Canada at the earliest time possible.”
The phase three clinical trial was stopped after the review of the first 150 random patients because it demonstrated clear clinical efficacy, and no safety concerns were identified. Treatment with sabizabulin was given as nine milligrams once daily.
Veru is a biopharmaceutical company developing novel medicines for COVID-19 and other related viral diseases and managing breast and prostate cancers. Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products.
Valeo Pharma Inc. (VPH) is unchanged, trading at $0.58 per share as of 11:36 a.m. ET.
